Robotic Surgery in India
Get Robotic Surgery at internationally accredited (JCI/NABH) Indian hospitals at a fraction of Western costs, with end-to-end international patient support — visa, travel, stay, and follow-up care.
Robotic Surgery in UAE
Robotic Surgery at leading UAE hospitals in Dubai and Abu Dhabi — world-class care closer to home, visa-free entry for many nationalities, international specialists, and modern facilities.
Overview
Robotic Cancer Surgery represents the most precise frontier in minimally invasive oncology, utilizing FDA-cleared systems such as the da Vinci Xi and Hugo RAS to achieve sub-millimetre surgical accuracy with significantly reduced blood loss, shorter hospital stays, and faster return to adjuvant therapy compared to open resection. Clinical outcomes across high-volume centres report overall procedure success and R0 (clear-margin) resection rates of 90–96% for eligible solid-tumour candidates, making the technology a benchmark standard for prostate, kidney, colorectal, gynaecologic, gastric, and thoracic cancers. GAF Healthcare connects international patients to JCI- and NABH-accredited hospitals in India and JCI- and DHA-licensed centres in Dubai and Abu Dhabi, offering end-to-end coordination at costs 40–60% below Western benchmarks without compromise to oncologic outcomes.
Hospital Stay: 3–7 days (varies by tumour site and extent of lymphadenectomy) • Total Stay in Country (Fit-to-Fly): 2–4 weeks (international long-haul clearance typically granted after wound review, drain removal, and DVT-risk assessment at post-operative day 14–21) • Success Rate: 90–96% R0 (clear-margin) resection rate in high-volume robotic oncology centres
What Is It?
Cancer surgery remains the cornerstone of curative intent treatment for most solid malignancies. When surgical resection is indicated — whether for radical prostatectomy, partial or radical nephrectomy, low anterior resection for rectal cancer, total laparoscopic hysterectomy with pelvic lymphadenectomy for cervical or endometrial cancer, sleeve lobectomy for non-small-cell lung cancer, or subtotal gastrectomy for gastric adenocarcinoma — the adequacy of the oncologic resection (defined by the R0 margin status and completeness of lymph node dissection) is the single most predictive variable for disease-free survival. Robotic surgical platforms extend the surgeon's dexterity into confined anatomical spaces — the pelvis, retroperitoneum, and mediastinum — where laparoscopic instruments are mechanically limited, thereby enabling more consistent achievement of nerve-sparing planes and extended template lymph node dissections without the physiological burden of open laparotomy.
The da Vinci Xi Surgical System and, more recently, the Medtronic Hugo RAS platform provide three-dimensional, 10× magnified vision, seven degrees of freedom with EndoWrist articulation, and tremor filtration, allowing surgeons to perform precise tissue dissection along embryological fascial planes (e.g., Denonvilliers' fascia in radical prostatectomy; the mesorectal envelope in total mesorectal excision for rectal cancer). These capabilities translate into measurable clinical advantages: intraoperative blood loss is typically reduced to under 150–200 mL for pelvic procedures, transfusion rates fall below 5%, and post-operative ileus duration is shortened compared to open surgery, enabling earlier initiation of adjuvant chemotherapy or radiation — a factor of independent prognostic significance.
The standard of care at high-volume robotic oncology centres integrates a multidisciplinary tumour board review prior to any surgical planning. This process incorporates molecular profiling (next-generation sequencing panels such as FoundationOne CDx or Guardant360), functional imaging (PET-CT with FDG, mpMRI, or PSMA-PET for prostate cancer staging), and a formal anaesthetic risk stratification using the ASA Physical Status Classification and CPET (cardiopulmonary exercise testing) where indicated. Patients in India and the UAE benefit from centres operating at annual robotic case volumes exceeding 400–800 procedures, a threshold consistently associated with lower conversion rates, shorter console times, and superior oncologic outcomes in peer-reviewed literature.
Candidates
• ELIGIBLE TUMOUR SITES: Prostate cancer (cT1c–T3a, PSA <20, Gleason/Grade Group 1–4 suitable for nerve-sparing RARP); renal cell carcinoma (tumours ≤7 cm, cT1–T2, amenable to robotic partial or radical nephrectomy); colorectal cancer (rectal cancer requiring TME, sigmoid, or right hemicolectomy); endometrial cancer (FIGO Stage I–III, requiring radical hysterectomy with pelvic ± para-aortic lymphadenectomy); cervical cancer (Stage IB1–IIA, following the updated Laparoscopic Approach to Cervical Cancer — LACC — trial protocols with enhanced informed consent); non-small-cell lung cancer (Stage I–II, amenable to robotic lobectomy or segmentectomy); gastric cancer (cT1–T3, requiring robotic subtotal or total gastrectomy with D2 lymphadenectomy)
• REQUIRED PRE-OPERATIVE DIAGNOSTICS: Contrast-enhanced CT chest/abdomen/pelvis (staging); FDG PET-CT or PSMA-PET (disease extent, nodal/metastatic status); multiparametric MRI (local staging for prostate, rectal, and endometrial primaries); complete blood count, comprehensive metabolic panel, coagulation profile (PT/INR, aPTT); serum tumour markers as applicable (PSA, CA-125, CEA, CA19-9); 12-lead ECG and 2D echocardiogram (LVEF assessment if cardiotoxic systemic therapy has preceded surgery); pulmonary function tests (FEV1, DLCO) for thoracic cases; histopathological confirmation via biopsy (core needle, TURP chips, or endoscopic biopsy); molecular/genomic profiling (MSI/MMR status, BRCA1/2, HER2, PD-L1) where systemic therapy sequencing is under consideration
• IDEAL CANDIDATE PROFILE: Performance status ECOG 0–2; organ-confined or locally advanced (non-metastatic) disease; BMI <40 (extreme obesity increases conversion risk and trocar-site complication rates); no prior major abdominal/pelvic surgeries with dense adhesions (relative contraindication requiring individual assessment); medically fit for general anaesthesia with ASA Class I–III
• CONTRAINDICATIONS: Distant metastatic disease where surgery is not part of an oligometastatic resection strategy; uncorrected coagulopathy; severe cardiopulmonary compromise (LVEF <30%, FEV1 <40% predicted) precluding safe Trendelenburg positioning and pneumoperitoneum; haemodynamic instability; prior pelvic radiation causing obliterative fibrosis (relative contraindication); active uncontrolled systemic infection
Procedure
STANDARD OPEN ONCOLOGIC SURGERY (COMPARATOR BASELINE)
Open radical resections — open radical prostatectomy (ORP), open colectomy, open nephrectomy — remain the historical gold standard but are associated with estimated blood loss of 500–1500 mL, 5–10 day hospital stays, 6–8 week convalescence, and higher rates of surgical site infection (3–10%). They remain indicated in cases of unresectable vascular involvement, prior complex abdominal surgery, or when robotic platforms are unavailable.
CONVENTIONAL LAPAROSCOPIC SURGERY
Minimally invasive but limited by two-dimensional vision, restricted instrument articulation (4 degrees of freedom), and significant surgeon ergonomic fatigue during prolonged pelvic dissections. Laparoscopic total mesorectal excision (L-TME) and laparoscopic radical prostatectomy are established but technically demanding procedures with a steep learning curve and higher conversion-to-open rates compared to robotic approaches.
ROBOTIC-ASSISTED SURGERY — PRIMARY RECOMMENDED APPROACH
The robotic platform is the preferred modality for complex oncologic resections requiring precise dissection in confined spaces. Key robotic procedures include:
• Robotic-Assisted Radical Prostatectomy (RARP): Includes bilateral pelvic lymph node dissection (extended template when intermediate-to-high risk), nerve-sparing technique (athermal dissection with Bulldog clips), and the Rocco stitch posterior reconstruction for early continence recovery. Positive surgical margin rates at high-volume centres: <10% for pT2 disease.
• Robotic Total Mesorectal Excision (R-TME): Transabdominal approach with sharp dissection within the holy plane; includes diverting loop ileostomy formation where anastomotic leak risk is elevated. The robotic platform's articulation is particularly advantageous for narrow male pelves and tumours at the anorectal junction.
• Robotic Partial Nephrectomy (RPN): Off-clamp or selective arterial clamping techniques to minimise warm ischaemia time (<25 minutes); utilises intraoperative near-infrared fluorescence imaging (Firefly, Iris Vision) with indocyanine green (ICG) to delineate tumour margins and renal perfusion in real time.
• Robotic Radical Hysterectomy (RRH) with Lymphadenectomy: Includes sentinel lymph node mapping with ICG injection into the cervical stroma, enabling selective ultra-staging with pathological ultrastaging protocols (MSKCC protocol) to reduce the morbidity of systematic lymphadenectomy.
• Robotic Lobectomy / Segmentectomy: Four-arm robotic approach for hilar lymph node dissection and bronchial/vascular stapling; evidence supports superior mediastinal lymph node yield versus VATS in prospective comparisons.
• Robotic Subtotal/Total Gastrectomy with D2 Lymphadenectomy: Standardised robotic D2 dissection achieving ≥15 lymph node yield as per JGCA guidelines; robotic platform reduces anastomotic complication rates in intracorporeal Roux-en-Y reconstruction.
NEO-ADJUVANT AND ADJUVANT INTEGRATION
Robotic surgery does not occur in isolation. Multi-modal treatment integration includes: neoadjuvant chemoradiation (nCRT with capecitabine or 5-FU + 50.4 Gy EBRT for rectal cancer prior to R-TME); neoadjuvant chemotherapy (FLOT4 protocol — fluorouracil, leucovorin, oxaliplatin, docetaxel — for resectable gastric adenocarcinoma); adjuvant targeted therapy (olaparib for BRCA-mutated prostate cancer post-RP; nivolumab for MSI-H colorectal cancer); androgen deprivation therapy combined with adjuvant radiation for high-risk prostate cancer post-RARP.
EMERGING TECHNOLOGIES AVAILABLE AT PARTNER CENTRES
• Single-Port Robotic Surgery (da Vinci SP): Indicated for radical prostatectomy and partial nephrectomy via a single 2.5 cm incision; available at select India and UAE centres.
• Robotic Natural Orifice Transluminal Endoscopic Surgery (R-NOTES): Investigational for select gynaecologic cases.
• AI-assisted intraoperative guidance: Real-time tissue tension analytics and anatomical landmark recognition (available on Hugo RAS and next-generation da Vinci platforms).
Cost of Robotic Surgery: India vs. UAE
The cost of robotic cancer surgery varies substantially depending on tumour site, extent of lymphadenectomy, neoadjuvant therapy status, and hospital tier. Both India and the UAE offer internationally accredited robotic oncology programmes; however, India's lower cost base — driven by lower operational costs and physician fees, not a reduction in technology or expertise — makes it the preferred destination for cost-conscious international patients. The UAE offers equivalent oncologic outcomes within a premium infrastructure, with the additional advantage of simplified visa access for patients from the GCC, Africa, and Europe. The table below reflects all-inclusive package estimates in USD for the most commonly performed robotic oncologic procedures (prostatectomy, colectomy, nephrectomy) inclusive of surgery, anaesthesia, robotic system charges, 5–7 night hospital stay, standard medications, and post-operative follow-up visits. Excluded costs (neoadjuvant chemotherapy, adjuvant radiation, implants such as ureteral stents or vascular staple loads above standard allocation) may add $500–$3,000.
| Destination | Estimated Cost (USD) | Key Advantage |
|---|---|---|
| India | $5,000 – $14,000 | ~53% less than the UAE |
| UAE (Dubai/Abu Dhabi) | $12,000 – $28,000 | Premium care, JCI/DHA accredited |
Estimates typically include surgery, hospital stay, and standard medications. Contact us for a personalised quote.
Recovery & Aftercare
PHASE 1 — PRE-TRAVEL & REMOTE CONSULTATION (Weeks 1–3 before travel) The patient uploads all existing histopathology reports, imaging (DICOM files), and laboratory results to the GAF Healthcare secure patient portal. A GAF case coordinator assigns a lead robotic oncology surgeon at the partner centre within 48 hours. The surgeon conducts a detailed teleconsultation, reviews staging, orders any missing workup remotely, and issues a formal surgical opinion and cost estimate. GAF Healthcare initiates e-Medical visa application for India (typically approved in 3–5 business days) or coordinates UAE entry visa / visa-on-arrival documentation. Flight and accommodation for patient and one attendant are pre-booked.
PHASE 2 — ARRIVAL & PRE-OPERATIVE WORKUP (Days 1–3 in country) Day 1: Airport pickup by GAF-assigned driver; check-in to hospital-adjacent accommodation or hospital room. Day 2: Dedicated pre-operative assessment day — blood panel, cross-match, repeat mpMRI or CT if staging images are >6 weeks old, anaesthetic evaluation (ASA classification, airway assessment, CPET if indicated), cardiac clearance (ECG ± ECHO), dietary consultation, and bowel preparation initiation for colorectal cases. Day 3: Tumour board case presentation (multidisciplinary team including robotic surgeon, medical oncologist, radiation oncologist, pathologist, and radiologist); surgical consent obtained with full discussion of nerve-sparing options, lymph node dissection template, and stoma planning where applicable. Patient admitted to hospital.
PHASE 3 — OPERATIVE DAY (Day 4) Patient transferred to robotic OR suite. General anaesthesia induced (TIVA or balanced volatile technique per anaesthesiologist preference). Patient positioned (steep Trendelenburg for pelvic cases; lateral decubitus for thoracic/renal cases). Robotic system docked (da Vinci Xi 4-arm configuration standard; SP system for single-port cases). Console surgeon performs procedure under 10× 3D vision. Average console time: 90–240 minutes depending on procedure complexity. Intraoperative frozen section analysis sent for margin confirmation. ICG fluorescence angiography used as applicable for perfusion assessment. Patient transferred to PACU; extubated same day in virtually all elective cases.
PHASE 4 — IN-HOSPITAL RECOVERY (Days 4–10) Day 1 post-op: Urinary catheter in situ (prostatectomy cases retain 7–14 days); surgical drains assessed; early ambulation initiated (physio-supervised walk within 16–24 hours per ERAS protocol — Enhanced Recovery After Surgery). Clear liquid diet commenced. Pain managed with multimodal analgesia: paracetamol + ketorolac + low-dose opioid PRN; epidural analgesia for open-converted or thoracic cases. Day 2–3: Diet advanced to soft/solid; drain output reviewed for chylous leak or haemorrhage; DVT prophylaxis with LMWH (enoxaparin 40 mg SC daily) commenced. Day 4–7: Discharge criteria assessed — afebrile, tolerating diet, pain controlled on oral analgesia, drain removed, pathology preliminary report issued. Most robotic oncology patients are discharged at Day 3–5 (prostate, kidney, thoracic) or Day 5–7 (colorectal, gastrectomy).
PHASE 5 — POST-DISCHARGE IN-COUNTRY RECOVERY (Days 10–21) Patient remains in country at partner hotel/serviced apartment. Post-operative clinic visit at Day 10–12: wound inspection, Hemovac/JP drain removal if still in situ, catheter removal (prostatectomy), and assessment of continence/functional recovery. Final histopathology report reviewed at this visit (typically available at Day 7–10): margin status, lymph node yield, pathological staging (ypT/ypN), and Ki-67/molecular receptor results. GAF coordinator facilitates rapid multidisciplinary oncology consultation to outline adjuvant treatment plan (radiation, chemotherapy, targeted therapy, or surveillance) before patient departs, enabling seamless handover to home oncologist.
PHASE 6 — FIT-TO-FLY CLEARANCE & DEPARTURE (Week 3–4) Formal fit-to-fly letter issued by the treating surgeon at or after Day 14–21, following DVT risk reassessment (Wells Score; Doppler ultrasound if high clinical suspicion), wound healing confirmation, and patient functional assessment (walking unaided, pain controlled, no fever or ileus). Patients are advised to use compression stockings, hydrate adequately, and ambulate every 60–90 minutes during long-haul flights. GAF coordinator provides translated discharge summary, pathology report, operative notes, and a structured oncology handover letter for the home treatment team.
PHASE 7 — REMOTE FOLLOW-UP (Months 1–12) GAF Healthcare facilitates teleconsultation follow-up at 6 weeks, 3 months, and 6 months post-surgery. PSA surveillance (prostatectomy), CT/PET restaging, and CEA monitoring (colorectal) are coordinated remotely. Any deviation from expected recovery trajectory prompts urgent escalation to the treating surgical team.
Risks & Considerations
Robotic cancer surgery, while significantly safer than open resection in terms of blood loss and wound complications, carries procedure-specific and platform-specific risks that every patient must understand before consent. General surgical risks include deep vein thrombosis (DVT) and pulmonary embolism (PE): absolute risk 1–3% in pelvic oncology cases despite LMWH prophylaxis, attributable in part to prolonged steep Trendelenburg positioning; anastomotic leak (colorectal and gastrectomy cases): incidence 3–7%, which may require temporary diverting stoma, IR-guided percutaneous drainage, or re-operation; conversion to open surgery: occurs in 2–5% of cases due to dense adhesions, uncontrolled haemorrhage, or loss of pneumoperitoneal integrity, with conversion rates higher in obese patients and those with prior abdominal surgery. Procedure-specific risks include: urinary incontinence and erectile dysfunction post-RARP (early continence rates of 70–85% at 3 months and 90–95% at 12 months at high-volume centres; erectile function recovery highly dependent on nerve-sparing feasibility and patient baseline function, with 40–70% of bilateral nerve-sparing candidates recovering penetrative function at 12–18 months with PDE5-inhibitor rehabilitation); ureteral injury in gynaecologic and colorectal robotic cases (incidence <1% but mandates immediate intraoperative repair); positive surgical margins (pT2+ PSM rates of 8–15% at lower-volume centres; <10% at high-volume expert centres — a key quality metric to request when evaluating surgeon credentials); chylous ascites following extended retroperitoneal lymph node dissection; port-site herniation (rare, <0.5%). Robotic platform-specific risks include instrument malfunction or system fault (extremely rare with modern da Vinci Xi; mandatory intraoperative safety protocols include immediate conversion capability). The oncologic risk of under-treatment — incomplete resection, inadequate lymph node yield — is the most consequential long-term risk and is directly mitigated by selecting surgeons with annual robotic case volumes exceeding 80–100 procedures per year for the specific procedure type. Patients with cervical cancer should be specifically counselled regarding the LACC trial data demonstrating inferior disease-free survival with minimally invasive radical hysterectomy versus open surgery in certain settings; GAF partner oncologists follow updated ESGO/SGO guidelines with case-by-case risk stratification and informed consent for this indication.
Top Hospitals for Robotic Surgery
The following JCI and NABH-accredited hospitals are among the most experienced in specialist care, with dedicated teams and high-volume programmes.
Apollo Hospitals
New Delhi, India
Medanta - The Medicity
Gurgaon, India
Kokilaben Dhirubhai Ambani Hospital
Mumbai, India
Tata Memorial Hospital
Mumbai, India
Top Doctors for Robotic Surgery
Internationally trained specialists in Surgical Oncology. Review their profiles, compare experience, and connect directly through GAF Healthcare.
Dr. Kanchan Kaur
MBBS, MS (General Surgery), MRCS
Surgical Oncologist (Breast)
Medanta - The Medicity, Gurgaon, India
22+ Yearsof experience
Dr. Kanchan Kaur is a senior breast cancer and general surgeon who serves as Senior Director — Breast Cancer at the Cancer Care division of Medanta – The Medicity, Gurgaon. With more than two decades of surgical experience, she has built a multidisciplinary breast practice that combines oncologic clarity with deep patient empathy. Dr. Kanchan is widely respected for her work in breast cancer awareness and early detection. She works closely with several… Read more
Dr. Ashwin Sunil Tamhankar
MBBS, MS, MCh Urology, DNB Urology, Vattikuti Robotic Uro-oncology Fellowship, RCS Laser Urological Robotic Fellowship, Olympus Laparoscopic Endo-Urology Fellowship
Surgical Oncologist & Robotic Uro-Oncologist
Apollo Hospitals, Navi Mumbai, Mumbai, India
9+ Yearsof experience
Dr. Ashwin Sunil Tamhankar is a Consultant in Surgical Oncology and Robotic Surgery based at Apollo Hospitals in Navi Mumbai, India. With over 9 years of specialized experience, he has established himself as a leading uro-oncologist, combining advanced robotic surgical techniques with precision cancer care. His credentials include MBBS, MS, MCh Urology, DNB Urology, and prestigious fellowships from the Vattikuti Institute, Royal College of Surgeons of… Read more
Dr. Asit Arora
MBBS, MS, MCh
GI & HPB Surgical Oncologist
Indraprastha Apollo Hospital, New Delhi, India
22+ Yearsof experience
Dr. Asit Arora is a Clinical Lead in GI and HPB Surgical Oncology at Indraprastha Apollo Hospital, New Delhi, bringing over 22 years of specialized expertise in managing complex gastrointestinal and hepatobiliary cancers. He holds an MBBS, MS in General Surgery, and an MCh in Gastrointestinal Surgery, and is widely recognized across India and internationally for his precision in radical oncologic resections and advanced abdominal cancer surgery. Dr. Arora… Read more
Dr. B. Niranjan Naik
MBBS, MS, Onco-Surgery, FIAGES
Surgical Oncologist
Paras Hospitals, Gurugram, India
22+ Yearsof experience
Dr. B. Niranjan Naik is Principal Director of Surgical Oncology and Director of Breast & Gastro-Intestinal Onco-Surgery at Paras Hospitals in Gurugram. With over 22 years of distinguished clinical experience, he is widely recognized as one of the leading breast cancer surgeons in the Delhi and Gurugram region. His credentials include MBBS and MS (General Surgery) from the All India Institute of Medical Sciences (AIIMS), New Delhi, followed by specialized… Read more
Dr. Belal Bin Asaf
MBBS, MS (Surgery), Fellowship in Thoracic Surgery, Certification as Robotic Console Surgeon, Observing Fellowship in VATS Lobectomy, Training in Minimally Invasive Esophagectomy
Thoracic Surgical Oncologist
Medanta — The Medicity, Gurugram, India
20+ Yearsof experience
Dr. Belal Bin Asaf is a distinguished Thoracic Surgical Oncologist and Director of Surgical Oncology at Medanta — The Medicity in Gurugram. With over 20 years of clinical experience, he has established himself as a pioneering leader in minimally invasive thoracic surgical oncology across India. His credentials include MBBS, MS in Surgery, Fellowship in Thoracic Surgery, and specialized certification as a Robotic Console Surgeon, combined with focused… Read more
Frequently Asked Questions — Robotic Surgery
The all-inclusive cost of robotic cancer surgery in India ranges from approximately $5,000 to $14,000 USD depending on the tumour site, complexity of the procedure, and extent of lymphadenectomy required. This range covers the most common robotic oncologic procedures — radical prostatectomy, robotic-assisted colectomy or total mesorectal excision, and robotic partial or radical nephrectomy — and includes the surgical team fee, robotic system charges, anaesthesia, a 5–7 night hospital stay, standard post-operative medications, and two post-operative follow-up visits. In the UAE (Dubai or Abu Dhabi), the equivalent procedures are estimated at $12,000 to $28,000 USD, reflecting higher operational infrastructure costs and physician fees, while maintaining equivalent oncologic standards at JCI- and DHA-accredited facilities. India is typically 40–60% less expensive than the UAE for the same procedure performed by surgeons with comparable robotic case volumes. Both destinations represent savings of 50–75% versus equivalent robotic surgery packages in the United States, United Kingdom, or Germany. Costs for neoadjuvant chemotherapy administered prior to surgery, adjuvant radiation therapy, advanced molecular diagnostics (e.g., next-generation sequencing panels), or specialised implants such as ureteral stents and additional staple cartridges may be itemised separately and should be discussed during the GAF Healthcare pre-travel financial counselling session.
For international patients, a minimum in-country stay of 3–4 weeks is strongly recommended following robotic cancer surgery, though the precise duration depends on the specific procedure performed and the individual patient's recovery trajectory. The typical in-hospital stay is 3–5 days for prostate, kidney, or thoracic robotic procedures and 5–7 days for colorectal or gastric resections. However, fitness for long-haul international air travel requires more than simple wound healing. The treating surgeon must formally clear the patient to fly, which involves: confirmation that all surgical drains have been removed, absence of post-operative fever or infection, confirmed ability to ambulate independently, adequate pain control on oral-only analgesia, and a formal DVT risk reassessment — including clinical scoring (Wells Criteria) and, if indicated, lower-limb Doppler ultrasound — at or after post-operative Day 14. For pelvic oncology procedures (prostatectomy, radical hysterectomy, rectal resection), where deep vein thrombosis risk is highest due to prolonged Trendelenburg positioning, fit-to-fly clearance is typically issued between Day 14 and Day 21. Patients who experienced complications, required prolonged drain management, or had anastomotic concerns may require 4–6 weeks in country. GAF Healthcare builds this recovery period into all travel planning and accommodation bookings, and the formal fit-to-fly letter — required by most airlines for post-surgical passengers — is prepared by the treating surgeon as part of the standard discharge package.
The success rate of robotic cancer surgery, when defined by the gold-standard oncologic metric of R0 resection — meaning complete surgical removal of the tumour with no cancer cells detected at the resection margins on histopathological examination — is consistently reported at 90–96% at high-volume robotic oncology centres. This is the most clinically meaningful measure of surgical success, as a positive surgical margin is an independent predictor of local recurrence and reduced disease-free survival regardless of tumour type. For robotic-assisted radical prostatectomy specifically, high-volume centres report pT2 positive surgical margin rates below 10% and pT3 positive margin rates of 15–30%, which are comparable to or superior to open radical prostatectomy in expert hands. For robotic total mesorectal excision in rectal cancer, the completeness of mesorectal excision (graded as complete or near-complete on pathological review) is achieved in over 90% of cases at specialist centres, a critical determinant of local recurrence rates below 5%. Functional outcomes — early urinary continence after prostatectomy (70–85% pad-free at 3 months), return of bowel function after colorectal resection (median 2–3 days), and respiratory function preservation after robotic lobectomy — also constitute important dimensions of success beyond margin status. It is essential to note that surgical success does not equate to cancer cure: long-term disease-free survival depends on pathological stage (pTNM), molecular tumour biology, and the completeness and adherence to adjuvant systemic therapy. GAF Healthcare partner centres provide integrated multidisciplinary oncology planning to ensure that surgical success is embedded within a comprehensive, guideline-concordant treatment strategy.
Why Plan Your Treatment Through Gaf Healthcare?
GAF Healthcare provides a fully integrated non-medical coordination service spanning every logistical touchpoint of the patient journey, from first enquiry to post-discharge follow-up.
VISA ASSISTANCE — INDIA: GAF Healthcare facilitates the e-Medical Visa (eMV) application for India, which permits a triple-entry stay of up to 60 days and is electronically approved within 72 hours to 5 business days. The eMV also covers one attendant (eM Attendant Visa). GAF provides a formal hospital invitation letter — a mandatory supporting document — on the patient's behalf within 24 hours of package confirmation.
VISA ASSISTANCE — UAE (DUBAI / ABU DHABI): Citizens of over 50 countries receive visa-on-arrival or visa-free access to the UAE for 30–90 days. For nationalities requiring a pre-arranged visa, GAF Healthcare coordinates a 30-day UAE medical treatment entry visa in partnership with the DHA-licensed host hospital. The UAE's geographical position as a 4–8 hour flight hub from most of Africa, South Asia, Eastern Europe, and the GCC makes it the most logistically accessible destination for many international patients.
AIRPORT TRANSFERS: Private, air-conditioned vehicle transfers are arranged for arrival and departure, including a wheelchair-accessible vehicle if required. For post-surgical departure, a stretcher-equipped transfer vehicle can be arranged upon medical advisement.
DEDICATED PATIENT COORDINATOR: Each patient is assigned a named GAF Healthcare coordinator who speaks the patient's language (Arabic, French, Russian, Swahili, or English as applicable) and is available via WhatsApp and direct call from the moment of first enquiry through the final teleconsultation follow-up. The coordinator accompanies the patient to key hospital appointments (pre-operative assessment, ward admission, discharge) where language support is required.
MEDICAL INTERPRETATION: Certified medical interpreters (not general translators) are available in 12 languages at partner hospitals in India (particularly in Chennai, Mumbai, Delhi, and Hyderabad) and at all JCI-accredited UAE centres. Surgical consent documentation is provided in the patient's native language.
ACCOMMODATION FOR ATTENDANT: GAF Healthcare pre-books hospital-adjacent serviced apartments, guesthouses, or hotel rooms for the patient's accompanying family member or caregiver. Pricing ranges from $25–$60/night in India to $80–$200/night in Dubai, depending on proximity and comfort tier. Extended-stay rates and hospital-caregiver guest bed availability are negotiated on the patient's behalf.
POST-DISCHARGE CARE COORDINATION: GAF arranges outpatient wound care, physiotherapy, catheter removal appointments, and access to a rapid-response medical consultation if any post-operative concern arises during the in-country recovery period. All final clinical documents — operative notes, histopathology reports, discharge summaries, adjuvant treatment plans — are translated and structured for direct handover to the patient's home oncologist.
Patients Also Explore
Other treatments commonly sought by patients considering Robotic Surgery.
Breast Cancer Treatment
Cancer Care
Lung Cancer Treatment
Cancer Care
Colonoscopy & Polypectomy
Gastroenterology
Hepatitis B Treatment
Gastroenterology